Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Deepak Cyril D’Souza, Marta DiForti, Suhas Ganesh, Tony P. George, Wayne Hall, Carsten Hjorthøj, Oliver Howes, Matcheri Keshavan, Robin M. Murray, Timothy B Nguyen, Godfrey D. Pearlson, Mohini Ranganathan, Alex Selloni, Nadia Solowij & Edoardo Spinazzola. (2022) Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. The World Journal of Biological Psychiatry 23:10, pages 719-742.
Read now
Read now
V. Yu. Skryabin, M. A. Vinnikova, E. V. Ezhkova, M. S. Titkov & R. A. Bulatova. (2021) Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study. Journal of Addictive Diseases 39:4, pages 513-525.
Read now
Read now
Melanie E. Bennett, Kristen R. Bradshaw & Lauren T. Catalano. (2017) Treatment of substance use disorders in schizophrenia. The American Journal of Drug and Alcohol Abuse 43:4, pages 377-390.
Read now
Read now
Carlos Roncero, Néstor Szerman, Antonio Terán, Carlos Pino, José María Vázquez, Elena Velasco, Marta García-Dorado & Miguel Casas. (2016) Professionals’ perception on the management of patients with dual disorders. Patient Preference and Adherence 10, pages 1855-1868.
Read now
Read now
Maju
Mathew Koola, HeidiJ. Wehring & DeannaL. Kelly. (2012) The Potential Role of Long-Acting Injectable Antipsychotics in People With Schizophrenia and Comorbid Substance Use. Journal of Dual Diagnosis 8:1, pages 50-61.
Read now
Read now
Nesrin Dilbaz & Aslı Enez Darçın. (2011) Şizofreni ve Madde Kullanım Bozukluğu Eş Tanılı Hastalarda Tedavi. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 21:1, pages 80-90.
Read now
Read now
MaryF. Brunette, Ree Dawson, ChristopherD. O’Keefe, Meera Narasimhan, DouglasL. Noordsy, Joanne Wojcik & AlanI. Green. (2011) A Randomized Trial of Clozapine Versus Other Antipsychotics for Cannabis Use Disorder in Patients With Schizophrenia. Journal of Dual Diagnosis 7:1-2, pages 50-63.
Read now
Read now
Élie Rizkallah, Emmanuel Stip, Simon Zhornitsky, Tania Pampoulova, Alain Gendron, Pierre-Paul Rompré, Jean-Pierre Chiasson & Stéphane Potvin. (2010) Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Expert Opinion on Pharmacotherapy 11:18, pages 2947-2951.
Read now
Read now
MaryF. Brunette, Ree Dawson, Christopher O'Keefe, Peter Buckley & AlanI. Green. (2009) An open label study of quetiapine in patients with schizophrenia and alcohol disorders. Mental Health and Substance Use 2:3, pages 203-211.
Read now
Read now
Thomas Wobrock & Michael Soyka. (2009) Pharmacotherapy of patients with schizophrenia and substance abuse. Expert Opinion on Pharmacotherapy 10:3, pages 353-367.
Read now
Read now
Stéphane Potvin, Tania Pampoulova, Olivier Lipp, Lahcen Aït Bentaleb, Pierre Lalonde & Emmanuel Stip. (2008) Working memory and depressive symptoms in patients with schizophrenia and substance use disorders. Cognitive Neuropsychiatry 13:4, pages 357-366.
Read now
Read now
Stéphane Potvin, Emmanuel Stip, Olivier Lipp, Marc-André Roy, Marie-France Demers, Roch-Hugo Bouchard & Alain Gendron. (2008) Anhedonia and Social Adaptation Predict Substance Abuse Evolution in Dual Diagnosis Schizophrenia. The American Journal of Drug and Alcohol Abuse 34:1, pages 75-82.
Read now
Read now
Articles from other publishers (42)
Heather Burrell Ward, Charles B. Nemeroff, Linda Carpenter, Adrienne Grzenda, William M. McDonald, Carolyn I. Rodriguez & Nina Vanessa Kraguljac. (2023) Substance use disorders in schizophrenia: Prevalence, etiology, biomarkers, and treatment. Personalized Medicine in Psychiatry 39-40, pages 100106.
Crossref
Crossref
Stefania Chiappini, Alessio Mosca, Andrea Miuli, Francesco Di Carlo, Giacomo d'Andrea, Alessandra Napolitano, Monica Santangelo, Corradina Esposito, Anna Rosazza, Elena Haefele, Gilberto Di Petta, Mauro Pettorruso, Stefano L. Sensi & Giovanni Martinotti. (2023) Aripiprazole once monthly as a maintenance treatment for patients with schizophrenia and alcohol/substance use disorder: an observational, real-world study. Advances in Dual Diagnosis.
Crossref
Crossref
Giovanni Martinotti, Stefania Chiappini, Alessio Mosca, Andrea Miuli, Maria Chiara Santovito, Mauro Pettorruso, Valentin Skryabin, Stefano L. Sensi & Massimo Di Giannantonio. (2022) Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical
Practice. Current Pharmaceutical Design 28:27, pages 2241-2259.
Crossref
Crossref
Dan Siskind, Erin Gallagher, Karl Winckel, Samantha Hollingworth, Steve Kisely, Joseph Firth, Christoph U Correll & Wade Marteene. (2021) Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. Schizophrenia Bulletin 47:4, pages 948-958.
Crossref
Crossref
N.N. Ivanets, M.A. Vinnikova, E.V. Ezhkova, M.S. Titkov & R.A. Bulatova. (2021) Clinical presentations and therapy of polysubstance dependence in patients with schizophrenia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 121:4, pages 63.
Crossref
Crossref
Friederike Ruppelt, Anja Rohenkohl, Vivien Kraft, Daniel Schöttle, Romy Schröter, Julia Gaianigo, Nathalie Werkle, Anne Daubmann, Anne Karow & Martin Lambert. (2020) Course, remission and recovery in patients with severe psychotic disorders with or without comorbid substance use disorders: Long-term outcome in evidence-based integrated care (ACCESS II study). Schizophrenia Research 222, pages 437-443.
Crossref
Crossref
Dusan Hirjak, Peter Gass, Michael Deuschle, F. Markus Leweke, Andreas Böhringer, Nadine Schenkel, Doris Borgwedel, Marco Heser, Antje Breisacher & Andreas Meyer-Lindenberg. (2019) Das ZI-Track-Konzept in der Behandlung psychotischer StörungenThe CIMH track concept in the treatment of psychotic disorders. Der Nervenarzt 91:3, pages 233-242.
Crossref
Crossref
N. N. Ivanets, M. A. Vinnikova, E. V. Ezhkova, M. S. Titkov & R. A. Bulatova. (2019) Aripiprazole and quetiapine in the treatment of patients with 'dual diagnosis' of schizophrenia and drug addiction. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:9, pages 52.
Crossref
Crossref
Itai Danovitch & David A. Gorelick. 2019. The Assessment and Treatment of Addiction. The Assessment and Treatment of Addiction
105
121
.
David A. Gorelick. 2019. Cannabis Use Disorders. Cannabis Use Disorders
113
125
.
Robin P Wilson & Sagnik Bhattacharyya. (2015) Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review. Journal of Psychopharmacology 30:2, pages 99-111.
Crossref
Crossref
Somaia Mohamed, Robert A. Rosenheck, Haiqun Lin, Marvin Swartz, Joseph McEvoy & Scott Stroup. (2015) Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. Journal of Nervous & Mental Disease 203:7, pages 486-492.
Crossref
Crossref
Brian R. Schultz, Lisette Rodriguez-Cabezas, Dan Angres & Matthew J. Smith. (2015) Treatment Strategies for Cannabis Use in Schizophrenia. Current Treatment Options in Psychiatry 2:2, pages 168-181.
Crossref
Crossref
Andre Tapp, Amanda Ernst Wood, Annette Kennedy, Patrick Sylvers, Nael Kilzieh & Andrew J. Saxon. (2015) Quetiapine for the treatment of cocaine use disorder. Drug and Alcohol Dependence 149, pages 18-24.
Crossref
Crossref
Sarah C. Akerman, Mary F. Brunette, Douglas L. Noordsy & Alan I. Green. (2014) Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders. Current Addiction Reports 1:4, pages 251-260.
Crossref
Crossref
Simon Zhornitsky, Ginette Aubin, Joelle Desfossés, Élie Rizkallah, Tania Pampoulova, Olivier Lipp, Jean-Pierre Chiasson, Emmanuel Stip & Stéphane Potvin. (2012) Predictors of Community Functioning in Schizophrenia and Substance Use Disorder Patients. Community Mental Health Journal 49:3, pages 317-322.
Crossref
Crossref
Nienke Dekker, Maarten Koeter & Wim Van Den Brink. (2012) Craving for cannabis in patients with psychotic disorder, their non‐affected siblings and healthy controls: psychometric analysis of the obsessive compulsive drug use scale. International Journal of Methods in Psychiatric Research 21:4, pages 286-300.
Crossref
Crossref
AR Lingford-Hughes, S Welch, L Peters & DJ Nutt. (2012) BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. Journal of Psychopharmacology 26:7, pages 899-952.
Crossref
Crossref
F. Markus Leweke, Thorsten M. Odorfer & J. Malte Bumb. 2012. Current Antipsychotics. Current Antipsychotics
165
185
.
Lara A. Ray, Pauline F. Chin, Andia Heydari & Karen Miotto. (2011) A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving. Psychopharmacology 217:3, pages 341-351.
Crossref
Crossref
Carlos Roncero, Carmen Barral, Lara Grau-Lopez, Diana Bachiller, Néstor Szerman, Miguel Casas,Pedro Ruiz. (2011) Protocols of Dual Diagnosis Intervention in Schizophrenia. Addictive Disorders & Their Treatment 10:3, pages 131-154.
Crossref
Crossref
David T. Chau, Jayme Ahmed, Thomas T. Wang, Haiyi Xie, Ree Dawson & Alan I. Green. (2011) Raclopride lessens the ability of clozapine to suppress alcohol drinking in Syrian golden hamsters. Neuropharmacology 61:4, pages 646-652.
Crossref
Crossref
Raouf Igue, Stéphane Potvin, Ramatoulaye Bah, Emmanuel Stip, Roch-Hugo Bouchard, Olivier Lipp, Alain Gendron & Edouard Kouassi. (2011) Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:7, pages 1695-1698.
Crossref
Crossref
Zoltan Makkos, Lilla Fejes, Gabriella Inczédy-Farkas, Akos Kassai-Farkas, Gabor Faludi & Judit Lazary. (2011) Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:1, pages 212-217.
Crossref
Crossref
Thomas Wobrock, Dirk Czesnik & Berend Malchow. 2011. Handbook of Schizophrenia Spectrum Disorders, Volume III. Handbook of Schizophrenia Spectrum Disorders, Volume III
321
363
.
Simon Zhornitsky, Stéphane Potvin, Emmanuel Stip & Pierre-Paul Rompré. (2010) Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine. European Neuropsychopharmacology 20:10, pages 695-703.
Crossref
Crossref
LARA A. RAY, ANDIA HEYDARI & TODD ZORICK. (2010) Quetiapine for the treatment of alcoholism: Scientific rationale and review of the literature. Drug and Alcohol Review 29:5, pages 568-575.
Crossref
Crossref
Jennifer H. Barnett, Trevor W. Robbins, Verity C. Leeson, Barbara J. Sahakian, Eileen M. Joyce & Andrew D. Blackwell. (2010) Assessing cognitive function in clinical trials of schizophrenia. Neuroscience & Biobehavioral Reviews 34:8, pages 1161-1177.
Crossref
Crossref
Alexandra Gallo, Stéphanie Lapointe, Emmanuel Stip, Stéphane Potvin & Pierre-Paul Rompré. (2010) Quetiapine blocks cocaine-induced enhancement of brain stimulation reward. Behavioural Brain Research 208:1, pages 163-168.
Crossref
Crossref
Carsten Hjorthøj, Allan Fohlmann & Merete Nordentoft. (2009) Reprint of “Treatment of cannabis use disorders in people with schizophrenia spectrum disorders — A systematic review”. Addictive Behaviors 34:10, pages 846-851.
Crossref
Crossref
Carsten Hjorthøj, Allan Fohlmann & Merete Nordentoft. (2009) Treatment of cannabis use disorders in people with schizophrenia spectrum disorders — A systematic review. Addictive Behaviors 34:6-7, pages 520-525.
Crossref
Crossref
Pierre Thomas, Köksal Alptekin, Mihai Gheorghe, Mauro Mauri, José Manuel Olivares & Michael Riedel. (2009) Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia. CNS Drugs 23:3, pages 193-212.
Crossref
Crossref
Zerrin Atakan. (2018) Managing cannabis use in people with severe mental illness: what can be done?. Advances in Psychiatric Treatment 15:1, pages 65-71.
Crossref
Crossref
Stéphane Potvin, Emmanuel Stip, Adrien Tempier, Tania Pampoulova, Lahcen Aït Bentaleb, Pierre Lalonde, Olivier Lipp, Philippe Goffaux & Serge Marchand. (2008) Pain perception in schizophrenia: No changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization. Journal of Psychiatric Research 42:12, pages 1010-1016.
Crossref
Crossref
T. Wobrock & M. Soyka. (2008) Pharmacotherapy of schizophrenia with comorbid substance use disorder — Reviewing the evidence and clinical recommendations. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32:6, pages 1375-1385.
Crossref
Crossref
St?phane Potvin, ?douard Kouassi, Olivier Lipp, Roch-Hugo Bouchard, Marc-Andr? Roy, Marie-France Demers, Alain Gendron, Giuseppe Astarita, Daniele Piomelli & Emmanuel Stip. (2008) Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. Journal of Psychopharmacology 22:3, pages 262-269.
Crossref
Crossref
Jin Hun Kim, Daeho Kim & Stephen R. Marder. (2008) Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32:4, pages 984-988.
Crossref
Crossref
Alan I. Green, Douglas L. Noordsy, Mary F. Brunette & Christopher O'Keefe. (2008) Substance abuse and schizophrenia: Pharmacotherapeutic intervention. Journal of Substance Abuse Treatment 34:1, pages 61-71.
Crossref
Crossref
T. Wobrock, R. D’Amelio & P. Falkai. (2007) Pharmakotherapie bei Schizophrenie und komorbider SubstanzstörungPharmacotherapy of schizophrenia and comorbid substance use disorder. Der Nervenarzt 79:1, pages 17-35.
Crossref
Crossref
Kathleen T. Brady, Marcia L. Verduin & Bryan K. Tolliver. (2007) Treatment of patients comorbid for addiction and other psychiatric disorders. Current Psychiatry Reports 9:5, pages 374-380.
Crossref
Crossref
Marie-Noëlle Levaux, Stéphane Potvin, Amir Ali Sepehry, Juliette Sablier, Adrianna Mendrek & Emmanuel Stip. (2020) Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB. European Psychiatry 22:2, pages 104-115.
Crossref
Crossref
Stéphane Potvin & Emmanuel Stip. (2008) Schizophrénie et toxicomanie : l’héritage du psychiatre Jean-Yves Roy. Santé mentale au Québec 32:2, pages 177-190.
Crossref
Crossref